Since TP53 is one of the most frequently mutated genes in cancer, reactivation of the wild-type p53 oncosuppressive properties and eliminating the mutant p53 GOF are potentially instrumental in personalized treatment of hundreds of thousands cancer patients worldwide. This evidence concerns the gene TP53 and cancer.